Coherus Set Sights On Taking Fifth Of US Pegfilgrastim Market

 
• By Aidan Fry

Having made a strong start with sales of over $120m in its first six months on the market, Coherus believes its Udenyca biosimilar could end 2019 with more than a fifth of the US pegfilgrastim market by volume.

PieChart
Coherus believes its Udenyca biosimilar can take at least 20% of the US pegfilgrastim market by the end of this year • Source: Shutterstock

More from Biosimilars

More from Products